These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Research advance of liquid biopsy in gastrointestinal stromal tumors].
    Author: Sun JY, Gao XD, Shen KT.
    Journal: Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep 25; 23(9):917-921. PubMed ID: 32927519.
    Abstract:
    Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumors in the gastrointestinal tract. Surgical resection is the only curative treatment, while imatinib is the first-line therapy for recurrent, metastatic, and unresectable GIST. However, more than half of GIST patients suffer from secondary resistance to imatinib within 2 years after treatment initiation. Therefore, early diagnosis, drug resistance and recurrence surveillance are critical for GIST patients. Liquid biopsy is a new method which utilizes the detection of tumor biomarkers in peripheral blood for early diagnosis and therapeutic efficacy assessment. In recent years, liquid biopsy has achieved significant research progress in several kinds of malignancy. This review aims at presenting an overview on research advance of liquid biopsy in GIST and may provide a new method for early diagnosis and therapeutic efficacy assessment of GIST. 胃肠间质瘤（GIST）是胃肠道最常见的间叶组织来源肿瘤，手术完整切除是其唯一的根治办法，而伊马替尼是转移复发或不可切除GIST患者的一线治疗药物。然而，超过一半GIST患者于伊马替尼治疗2年内出现继发性耐药，进而导致肿瘤复发。因此，早期诊断、监测耐药性及肿瘤复发对GIST患者具有重要意义。液体活检是一项检测人体外周血中的肿瘤细胞标记，用于肿瘤早期诊断和治疗效果评估等的新兴技术。近几年来，液体活检技术在多种恶性肿瘤领域获得重要研究进展。本文将综述液体活检技术在GIST中的临床及基础研究进展，旨在为GIST的早期诊断、治疗效果评估等提供新的检测方法。.
    [Abstract] [Full Text] [Related] [New Search]